A clinician sees a pattern in their own patients. They run the numbers to check it, and the numbers seem to confirm what they already suspected. But that confirmation might not be real. “Often a clinician at the point of care will come to us with a hunch — ‘I’ve seen a bunch of these…
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s triple agonist, retatrutide, demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes, the company announced today. Retatrutide is an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist. The drug met the primary and key secondary endpoints, delivering superior A1C reduction and…

